Insurers View JUPITER With Caution; Can Benefit Be Achieved With Generics?
Executive Summary
As insurers begin to review the details of AstraZeneca's headline-making outcomes study on Crestor - the JUPITER trial - a key question is whether the benefit found can also be extrapolated to less expensive statins, including generics
You may also be interested in...
Crestor Advisory Committee For Primary Prevention Of CV Disease To Focus On Adverse Events
AstraZeneca's JUPITER study could be added to the statin's label if advisory committee is not troubled by signals of gastrointestinal disorders, "confusional state" and diabetes.
JUPITER Shines Celestial Glow On Statin Use; Docs Ready, But Are Payers?
A few months after the release of AstraZeneca's widely heralded JUPITER Crestor study, physicians seem prepared to prescribe statins more broadly based on that evidence, according to discussion at the American College of Cardiology annual meeting
JUPITER Shines Celestial Glow On Statin Use; Docs Ready, But Are Payers?
A few months after the release of AstraZeneca's widely heralded JUPITER Crestor study, physicians seem prepared to prescribe statins more broadly based on that evidence, according to discussion at the American College of Cardiology annual meeting